Health Benefits of Anti-aging Drugs

Piskovatska, Veronika; Strilbytska, Olha; Koliada, Alexander; Vaiserman, Alexander; Lushchak, Oleh

doi:10.1007/978-981-13-3681-2_13

Cited by 44 publications

(31 citation statements)

References 300 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Correlations between oxidative stress and carcinogenesis may be used for therapeutic aims in the future. For example, the effect of oxidative stress on carcinogenesis according to various studies shows significant changes during the use of metformin [ 223 , 224 ]. The anti-cancer property of metformin is not fully examined.…”

Section: Oxidative Stress Parkinson’s Disease and Cancermentioning

confidence: 99%

The Links between Parkinson’s Disease and Cancer

et al. 2020

View full text Add to dashboard Cite

Epidemiologic studies indicate a decreased incidence of most cancer types in Parkinson’s disease (PD) patients. However, some neoplasms are associated with a higher risk of occurrence in PD patients. Both pathologies share some common biological pathways. Although the etiologies of PD and cancer are multifactorial, some factors associated with PD, such as α-synuclein aggregation; mutations of PINK1, PARKIN, and DJ-1; mitochondrial dysfunction; and oxidative stress can also be involved in cancer proliferation or cancer suppression. The main protein associated with PD, i.e., α-synuclein, can be involved in some types of neoplastic formations. On the other hand, however, its downregulation has been found in the other cancers. PINK1 can act as oncogenic or a tumor suppressor. PARKIN dysfunction may lead to some cancers’ growth, and its expression may be associated with some tumors’ suppression. DJ-1 mutation is involved in PD pathogenesis, but its increased expression was found in some neoplasms, such as melanoma or breast, lung, colorectal, uterine, hepatocellular, and nasopharyngeal cancers. Both mitochondrial dysfunction and oxidative stress are involved in PD and cancer development. The aim of this review is to summarize the possible associations between PD and carcinogenesis.

show abstract

Section: Oxidative Stress Parkinson’s Disease and Cancermentioning

confidence: 99%

The Links between Parkinson’s Disease and Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The lists of substances that have been shown in at least some experiments with animal models, ranging from nematodes to primates, to extend their lifespans by presumably slowing down their aging may be found in the public databases Geroprotectors 3 and DrugAge 4 , which have accumulated about four hundred entries. However, not more than a score of such substances are believed to produce consistent results in mammals and thus are evaluated for their effects in humans in clinical trials or/and population surveys (Qian and Liu, 2018;Piskovatska et al, 2019;Gonzalez-Freire et al, 2020). Those of the substances that have been suggested for treating COVID-19 are included in Figure 3.…”

Section: Grounds For Using Anti-aging Interventions To Combat Covid-19mentioning

confidence: 99%

COVID-19: A Challenge to Physiology of Aging

Golubev

2020

Front. Physiol.

View full text Add to dashboard Cite

The death toll of the current COVID-19 pandemic is strongly biased toward the elderly. COVID-19 case fatality rate (CFR) increases with age exponentially, its doubling time being about 7 years, irrespective of countries and epidemic stages. The same age-dependent mortality pattern known as the Gompertz law is featured by the total mortality and its main constituents attributed to cardiovascular, metabolic, neurological, and oncological diseases. Among patients dying of COVID-19, most have at least one of these conditions, whereas none is found in most of those who pass it successfully. Thus, gerontology is indispensable in dealing with the pandemic, which becomes a benchmark for validating the gerontological concepts and advances. The two basic alternative gerontological concepts imply that either aging results from the accumulation of stochastic damage, or is programmed. Based on these different grounds, several putative anti-aging drugs have been proposed as adjuvant means for COVID-19 prevention and/or treatment. These proposals are reviewed in the context of attributing the molecular targets of these drugs to the signaling pathways between the sensors of resource availability and the molecular mechanisms that allocate resources to storage, growth and reproduction or to self-maintenance and repair. Each of the drugs appears to reproduce only a part of the physiological responses to reduced resource availability caused by either dietary calories restriction or physical activity promotion, which are the most robust means of mitigating the adverse manifestations of aging. In the pathophysiological terms, the conditions of the endothelium, which worsen as age increases and may be significantly improved by the physical activity, is a common limiting factor for the abilities to withstand both physical stresses and challenges imposed by COVID-19. However, the current anti-epidemic measures promote sedentary indoor lifestyles, at odds with the most efficient behavioral interventions known to decrease the vulnerability to both the severe forms of COVID-19 and the prevalent aging-associated diseases. To achieve a proper balance in public health approaches to COVID-19, gerontologists should be involved in crosstalk between virologists, therapists, epidemiologists, and policy makers. The present publication suggests a conceptual background for that.

show abstract

“…As dietary interventions prove to be challenging for most people to adhere to in the long term [ 28 , 29 ] and genetic interventions still suffer from many technical, ethical and safety problems [ 30 , 31 ], the main potential in the near future for human clinical translation is the development of pharmacological interventions in the aging process: so-called geroprotective drugs [ 22 , 32 , 33 , 34 ]. Multiple drugs such as rapamycin, metformin, spermidine, senolytics, lithium and acarbose have been found to extend lifespan in model organisms [ 21 , 22 , 32 , 35 ]. In fact, the first randomized, controlled clinical trial, the TAME (Targeting Aging with Metformin) trial, has recently cleared the last obstacle, securing enough funding, and so the trial should start in the near future [ 36 ].…”

Section: Introductionmentioning

confidence: 99%

Phenotypic Screening in C. elegans as a Tool for the Discovery of New Geroprotective Drugs

Bulterijs

Braeckman

2020

Pharmaceuticals

View full text Add to dashboard Cite

Population aging is one of the largest challenges of the 21st century. As more people live to advanced ages, the prevalence of age-related diseases and disabilities will increase placing an ever larger burden on our healthcare system. A potential solution to this conundrum is to develop treatments that prevent, delay or reduce the severity of age-related diseases by decreasing the rate of the aging process. This ambition has been accomplished in model organisms through dietary, genetic and pharmacological interventions. The pharmacological approaches hold the greatest opportunity for successful translation to the clinic. The discovery of such pharmacological interventions in aging requires high-throughput screening strategies. However, the majority of screens performed for geroprotective drugs in C. elegans so far are rather low throughput. Therefore, the development of high-throughput screening strategies is of utmost importance.

show abstract

Health Benefits of Anti-aging Drugs

Cited by 44 publications

References 300 publications

The Links between Parkinson’s Disease and Cancer

The Links between Parkinson’s Disease and Cancer

COVID-19: A Challenge to Physiology of Aging

Phenotypic Screening in C. elegans as a Tool for the Discovery of New Geroprotective Drugs

Contact Info

Product

Resources

About